CABA Long Call Strategy
CABA (Cabaletta Bio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
CABA (Cabaletta Bio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $345.6M, a beta of 3.17 versus the broader market, a 52-week range of 1.26-4.23, average daily share volume of 3.1M, a public-listing history dating back to 2019, approximately 161 full-time employees. These structural characteristics shape how CABA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 3.17 indicates CABA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on CABA?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current CABA snapshot
As of May 15, 2026, spot at $3.33, ATM IV 85.80%, IV rank 8.88%, expected move 24.60%. The long call on CABA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on CABA specifically: CABA IV at 85.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a CABA long call, with a market-implied 1-standard-deviation move of approximately 24.60% (roughly $0.82 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CABA expiries trade a higher absolute premium for lower per-day decay. Position sizing on CABA should anchor to the underlying notional of $3.33 per share and to the trader's directional view on CABA stock.
CABA long call setup
The CABA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CABA near $3.33, the first option leg uses a $3.33 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CABA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CABA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.33 | N/A |
CABA long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CABA long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CABA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on CABA
Long calls on CABA express a bullish thesis with defined risk; traders use them ahead of CABA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CABA thesis for this long call
The market-implied 1-standard-deviation range for CABA extends from approximately $2.51 on the downside to $4.15 on the upside. A CABA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CABA IV rank near 8.88% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CABA at 85.80%. As a Healthcare name, CABA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CABA-specific events.
CABA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CABA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CABA alongside the broader basket even when CABA-specific fundamentals are unchanged. Long-premium structures like a long call on CABA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CABA chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CABA?
- A long call on CABA is the long call strategy applied to CABA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CABA stock trading near $3.33, the strikes shown on this page are snapped to the nearest listed CABA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CABA long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CABA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 85.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CABA long call?
- The breakeven for the CABA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CABA market-implied 1-standard-deviation expected move is approximately 24.60%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CABA?
- Long calls on CABA express a bullish thesis with defined risk; traders use them ahead of CABA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CABA implied volatility affect this long call?
- CABA ATM IV is at 85.80% with IV rank near 8.88%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.